Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 14Bortezomib 9Peripheral Blood Stem Cell Transplantation 6fludarabine phosphate 5Filgrastim 5temsirolimus 4tanespimycin 4alvocidib 4Magnetic Resonance Spectroscopy 4Indium 4Cyclophosphamide 4ibritumomab tiuxetan 3Vorinostat 3Sirolimus 3Carboplatin 3sargramostim 2oblimersen 2ibrutinib 2belinostat 2Radiotherapy 2Pharmacogenomic Testing 2Methotrexate 2MK 2206 2Lenalidomide 2Interleukin-12 Subunit p35 2Interferon-alpha 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Cyclosporine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Waldenstrom Macroglobulinemia × oprelvekin × Clear all
NCT00012298 2018-08-09

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
81 enrolled 16 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡